Organon & Co. (NYSE:OGN) Hits New 12-Month High – Should You Buy?

Organon & Co. (NYSE:OGN) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $13.60 and last traded at $13.5850, with a volume of 473808 shares. The stock had previously closed at $13.54.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on OGN shares. Weiss Ratings raised Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and upped their price target for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th. BNP Paribas Exane reiterated a “neutral” rating and issued a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Finally, Zacks Research upgraded shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $11.40.

Organon & Co. Price Performance

The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47. The stock has a market cap of $3.57 billion, a P/E ratio of 14.61, a P/E/G ratio of 1.25 and a beta of 1.55. The firm has a 50 day moving average price of $13.00 and a 200 day moving average price of $9.41.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The company’s revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.02 earnings per share. On average, analysts forecast that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Monday, May 11th were paid a $0.02 dividend. The ex-dividend date of this dividend was Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio is 8.60%.

Insider Activity at Organon & Co.

In other news, SVP Lynette Holzbaur acquired 26,448 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were purchased at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the transaction, the senior vice president directly owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.62% of the stock is owned by insiders.

Institutional Investors Weigh In On Organon & Co.

Institutional investors have recently bought and sold shares of the business. WNY Asset Management LLC purchased a new position in shares of Organon & Co. in the first quarter valued at about $64,000. Orographic Financial Advisors LLC purchased a new position in Organon & Co. in the 1st quarter worth approximately $1,522,000. Amundi boosted its stake in Organon & Co. by 84.0% in the 1st quarter. Amundi now owns 80,944 shares of the company’s stock worth $485,000 after purchasing an additional 36,961 shares during the period. California State Teachers Retirement System grew its holdings in Organon & Co. by 34.8% during the 1st quarter. California State Teachers Retirement System now owns 327,075 shares of the company’s stock valued at $1,959,000 after buying an additional 84,497 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in Organon & Co. by 8.5% during the 1st quarter. Royal Bank of Canada now owns 299,663 shares of the company’s stock valued at $1,794,000 after buying an additional 23,456 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.